Phase 2 Interstitial Lung Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are 40 years of age or older at the time of signing the consent form
• You have agreed to take part by signing and dating a consent form before the trial begins
• You are male, or if female, you are no longer able to become pregnant — either because you have had surgery to prevent pregnancy (such as removal of the womb, fallopian tubes, or ovaries), or because you have been through menopause (no periods for 12 months without another medical reason); male participants with female partners who could become pregnant must use a condom during treatment and for a set period after their last dose
• You have been officially diagnosed with a lung disease called IPF (Idiopathic Pulmonary Fibrosis) before the first study visit, confirmed using the most recent specialist guidelines from 2022
• You have had a specific type of chest scan (called an HRCT) within the last 12 months showing a pattern consistent with IPF, as confirmed by a central review team
• The scarring in your lungs covers at least 20% of your lungs, as shown on your chest scan and confirmed by a central review
• Your lungs can hold and move at least 45% of the air expected for a healthy person of your age and size (confirmed by a breathing test)
• Your lungs are able to transfer at least 20% of the oxygen expected for a healthy person of your age and size (confirmed by a breathing test)

Who may not be able to join:

• You have had a sudden, serious worsening of your IPF in the 12 weeks before the first study visit or during the screening period
• Your breathing tests show a significant blockage in your airways
• You have had a chest or lung infection that needed treatment within the 4 weeks before the first study visit or during the screening period
• You have significant high blood pressure in the arteries of your lungs or signs of serious right-side heart failure (confirm with trial site)
• You have been taking IPF medications called nintedanib or pirfenidone for less than 12 weeks before the first study visit, or you are planning to start either of these medications within the first 12 weeks of the trial, or you are taking both of these medications together
• You have serious heart or blood pressure problems, including very high blood pressure that is not controlled by medication, or a heart attack, stroke, or mini-stroke within the past 6 months, or unstable chest pain (angina) within the past 6 months
• Your doctors estimate that another serious health condition (not IPF) means you are unlikely to live for more than 2.5 years

Important: Always verify eligibility with the trial site directly before applying.